<DOC>
	<DOCNO>NCT00142883</DOCNO>
	<brief_summary>Gamma-aminobutyric acid ( GABA ) type neurotransmitter , chemical transmits information within brain part body . By lower level another neurotransmitter call dopamine , GABA may ability diminish cocaine craving addict . The purpose study gather information interaction cocaine select GABA enhance medication individual addict cocaine . This may lead future clinical study use GABA medication treat cocaine addiction .</brief_summary>
	<brief_title>The Effects GABA Enhancing Medications Individuals Addicted Cocaine - 3</brief_title>
	<detailed_description>GABA inhibitory neurotransmitter find primarily brain . High GABA level result low level dopamine , another neurotransmitter brain 's `` feel good '' chemical play primary role cocaine drug addiction . Cravings cocaine reduce lower dopamine level . This make GABA-altering medication potential treatment cocaine addiction . This study involve five GABA enhance medication : tiagabine , topiramate , valproic acid , baclofen , progesterone . The purpose study evaluate interaction GABA medication cocaine term safety craving response . In turn , finding may guide future cocaine pharmacotherapy trial . This 6-day inpatient study begin orientation session familiarize participant study procedure . The evening Day 1 , participant receive placebo medication . On Days 2 4 , participant receive one five GABA medication . The GABA medication give gradually increase dos attain therapeutic level maintain safety minimize side effect . Three experimental cocaine session take place ; one participant receive placebo medication two participant receive GABA medication . During session , cocaine administer intravenously three increase dos , separate 30-minute interval . This allow participant ' subjective physiological response cocaine administration return baseline level next dose . Blood drawn dose ; heart rate , blood pressure , ECG monitor throughout session . At end session , questionnaire administer assess effect cocaine relate mood state , well allow participant report adverse event , depression , crave , withdrawal symptom . This study close publish .</detailed_description>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>Meets DSMIV criterion cocaine dependence History smoke intravenous cocaine use average least week 6 month period Positive urine test cocaine No current medical problem Normal electrocardiogram If female , willing use contraception throughout study Seeking treatment cocaine dependence Current major psychiatric illness , include mood disorder , psychotic disorder , anxiety disorder Current dependence alcohol drug cocaine nicotine History major medical illness , include liver disease , suspect known cancer , thrombophlebitis , medical condition consider unsafe study participant investigator Known allergy study medication Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>addiction , crack , cocaine</keyword>
</DOC>